17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

(2017) Rina M. Mbofung et al.   Nature Communications

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation

(2015) Manali Phadke et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

(2014) Moriah H. Nissan et al.   CANCER RESEARCH

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

(2014) T. Smyth et al.   MOLECULAR CANCER THERAPEUTICS

Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

(2013) S. R. Goding et al.   JOURNAL OF IMMUNOLOGY

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

(2012) K. H. T. Paraiso et al.   CLINICAL CANCER RESEARCH

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

Determination of Melanin Synthetic Pathways

(2011) Vincent J. Hearing   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

(2010) Simon Pacey et al.   INVESTIGATIONAL NEW DRUGS

Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma

(2010) Ying Xie et al.   JOURNAL OF EXPERIMENTAL MEDICINE

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-specific Th17-polarized cells eradicate large established melanoma

(2008) P. Muranski et al.   BLOOD

Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives

(2008) Y. Fukuyo et al.   CANCER RESEARCH

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

(2008) U. Banerji et al.   MOLECULAR CANCER THERAPEUTICS

Neurofibromin as a regulator of melanocyte development and differentiation

(2007) G. Diwakar et al.   JOURNAL OF CELL SCIENCE

Methodology for Evaluation of Melanin Content and Production of Pigment Cells in Vitro

(2007) Dan-Ning Hu   PHOTOCHEMISTRY AND PHOTOBIOLOGY